When.com Web Search

  1. Ads

    related to: new medication for psoriasis

Search results

  1. Results From The WOW.Com Content Network
  2. Guselkumab - Wikipedia

    en.wikipedia.org/wiki/Guselkumab

    Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, and ulcerative colitis. [ 5 ] [ 7 ] [ 8 ] [ 9 ]

  3. Secukinumab - Wikipedia

    en.wikipedia.org/wiki/Secukinumab

    Secukinumab inhibits a member of the cytokine family, interleukin 17A, which is produced mainly by inflammatory T helper 17 cells. [11] IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in ...

  4. Tapinarof - Wikipedia

    en.wikipedia.org/wiki/Tapinarof

    Tapinarof, also known as benvitimod and sold under the brand name Vtama, is a medication used for the treatment of plaque psoriasis. [1] The medication is applied to the skin. [1] Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. [2] [3]

  5. Deucravacitinib - Wikipedia

    en.wikipedia.org/wiki/Deucravacitinib

    Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. [7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. [7] It was developed by Bristol Myers Squibb. [10]

  6. Risankizumab - Wikipedia

    en.wikipedia.org/wiki/Risankizumab

    Risankizumab was approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe plaque psoriasis in April 2019. [13] [10] [14]The FDA approved risankizumab based on evidence primarily from five clinical trials (Trial 1/NCT02684370, Trial 2/NCT02684357, Trial 3/NCT02672852, Trial 4/ NCT02694523, and Trial 5/NCT02054481) of 1606 participants with moderate to severe ...

  7. Spesolimab - Wikipedia

    en.wikipedia.org/wiki/Spesolimab

    Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis (GPP). [4] It is an interleukin-36 receptor (IL-36R) antagonist. [ 4 ] [ 6 ] It is given via injection into a vein.

  1. Ads

    related to: new medication for psoriasis